中期PET-CT在淋巴瘤一线治疗决策中的应用

黄琳琳; 赵毅; 何静松

doi:10.1631/jzus.B2200644

Your Location：

Home >

Browse articles >

中期PET-CT在淋巴瘤一线治疗决策中的应用

Scan for full text

文章被引用时，请邮件提醒。

Submit

Review | Updated：2023-09-25

中期PET-CT在淋巴瘤一线治疗决策中的应用
Application of interim PET-CT in first-line treatment decision-making for lymphoma
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2023年24卷第10期页码：905-921
Affiliations：

1.Bone Marrow Transplantation Center, Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
Funds：

the National Natural Science Foundation of China(82270206);the Key Project of Zhejiang Provincial Natural Science Foundation of China(LZ22H160009)
DOI：10.1631/jzus.B2200644
中图分类号：
CSTR：

黄琳琳, 赵毅, 何静松. 中期PET-CT在淋巴瘤一线治疗决策中的应用[J]. 浙江大学学报（英文版）（B辑：生物医学和生物技术）, 2023,24(10):905-921.

Linlin HUANG, Yi ZHAO, Jingsong HE. Application of interim PET-CT in first-line treatment decision-making for lymphoma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2023,24(10):905-921.
黄琳琳, 赵毅, 何静松. 中期PET-CT在淋巴瘤一线治疗决策中的应用[J]. 浙江大学学报（英文版）（B辑：生物医学和生物技术）, 2023,24(10):905-921. DOI： 10.1631/jzus.B2200644.

Linlin HUANG, Yi ZHAO, Jingsong HE. Application of interim PET-CT in first-line treatment decision-making for lymphoma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2023,24(10):905-921. DOI： 10.1631/jzus.B2200644.

摘要

随着淋巴瘤治疗手段的发展与改进，患者的生存得到了极大的改善。然而，目前的治疗方法存在不同程度的副作用，因此需尽可能减少治疗带来的不良反应，并根据患者的情况实施个体化治疗。基于此，尽早识别高危人群并进行针对性治疗是延长患者生存时间和提高生活质量的重要策略。中期正电子发射计算机断层扫描（PET-CT）具有较高的预后价值，可以反映化疗敏感性并识别在该方案下治疗可能失败的患者。迄今为止，已经进行了多项关于中期PET（iPET）引导治疗的前瞻性临床研究。本综述重点关注上述研究中涉及的治疗策略以及iPET评估的方法和时间，通过探索iPET指导治疗的效果和存在的问题，以期iPET在治疗引导中能发挥更大的价值。

Abstract

Recent advances in lymphoma treatment have significantly improved the survival of patients; however, the current approaches also have varying side effects. To overcome these, it is critical to implement individualized treatment according to the patient’s condition. Therefore, the early identification of high-risk groups and targeted treatment are important strategies for prolonging the survival time and improving the quality of life of patients. Interim positron emission tomography-computed tomography (PET-CT) has a high prognostic value, which can reflect chemosensitivity and identify patients for whom treatment may fail under this regimen. To date, many prospective clinical studies on interim PET (iPET)‍-adapted therapy have been conducted. In this review, we focus on the treatment strategies entailed in these studies, as well as the means and timing of iPET assessment, with the aim of exploring the efficacy and existing issues regarding iPET-adapted treatment. It is expected that the improved use of PET-CT examination can facilitate treatment decision-making to identify precise treatment options.

关键词

正电子发射计算机断层扫描（PET-CT）淋巴瘤中期PET（iPET）引导的淋巴瘤治疗

Keywords

Positron emission tomography-computed tomography (PET-CT)LymphomaInterim PET (iPET)‍-adapted therapy

references

Allen PB, Savas H, Evens AM, et al., 2021. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood, 137(10):1318-1326. https://doi.org/10.1182/blood.2020007400https://doi.org/10.1182/blood.2020007400

André MPE, Girinsky T, Federico M, et al., 2017. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 35(16):1786-1794. https://doi.org/10.1200/JCO.2016.68.6394https://doi.org/10.1200/JCO.2016.68.6394

Bailly C, Cléry PF, Faivre-Chauvet A, et al., 2017. Immuno-PET for clinical theranostic approaches. Int J Mol Sci, 18(1):57. https://doi.org/10.3390/ijms18010057https://doi.org/10.3390/ijms18010057

Barrington SF, Meignan M, 2019. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med, 60(8):‍1096-1102. https://doi.org/10.2967/jnumed.119.227249https://doi.org/10.2967/jnumed.119.227249

Barrington SF, Trotman J, 2021. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol, 8(1):e80-e93. https://doi.org/10.1016/S2352-3026(20)30365-3https://doi.org/10.1016/S2352-3026(20)30365-3

Behringer K, Mueller H, Goergen H, et al., 2013. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol, 31(2):231-239. https://doi.org/10.1200/JCO.2012.44.3721https://doi.org/10.1200/JCO.2012.44.3721

Berthon B, Marshall C, Evans M, et al., 2016. ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography. Phys Med Biol, 61(13):4855-4869. https://doi.org/10.1088/0031-9155/61/13/4855https://doi.org/10.1088/0031-9155/61/13/4855

Bologna S, Vander Borght T, Briere J, et al., 2021. Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09-1B trial. Hematol Oncol, 39(S2):31-32. https://doi.org/10.1002/hon.5_2879https://doi.org/10.1002/hon.5_2879

Borchmann P, Haverkamp H, Diehl V, et al., 2011. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol, 29(32):4234-4242. https://doi.org/10.1200/JCO.2010.33.9549https://doi.org/10.1200/JCO.2010.33.9549

Borchmann P, Goergen H, Kobe C, et al., 2017. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114):2790-2802. https://doi.org/10.1016/S0140-6736(17)32134-7https://doi.org/10.1016/S0140-6736(17)32134-7

Borchmann P, Plütschow A, Kobe C, et al., 2021. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 22(2):223-234. https://doi.org/10.1016/S1470-2045(20)30601-Xhttps://doi.org/10.1016/S1470-2045(20)30601-X

Boursier C, Perrin M, Bordonne M, et al., 2022. Early 18F-FDG PET flare-up phenomenon after CAR T-cell therapy in lymphoma. Clin Nucl Med, 47(2):e152-e153. https://doi.org/10.1097/RLU.0000000000003870https://doi.org/10.1097/RLU.0000000000003870

Carras S, Dubois B, Senecal D, et al., 2018. Interim PET response-adapted strategy in untreated advanced stage Hodgkin lymphoma: results of GOELAMS LH 2007 phase 2 multicentric trial. Clin Lymphoma Myeloma Leuk, 18(3):191-198. https://doi.org/10.1016/j.clml.2018.01.003https://doi.org/10.1016/j.clml.2018.01.003

Casasnovas RO, Ysebaert L, Thieblemont C, et al., 2017. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood, 130(11):1315-1326. https://doi.org/10.1182/blood-2017-02-766691https://doi.org/10.1182/blood-2017-02-766691

Casasnovas RO, Bouabdallah R, Brice P, et al., 2019. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol, 20(2):‍202-215. https://doi.org/10.1016/S1470-2045(18)30784-8https://doi.org/10.1016/S1470-2045(18)30784-8

Cashen AF, Dehdashti F, Luo JQ, et al., 2011. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med, 52(3):‍386-392. https://doi.org/10.2967/jnumed.110.082586https://doi.org/10.2967/jnumed.110.082586

Cheson BD, 2018. PET/CT in lymphoma: current overview and future directions. Semin Nucl Med, 48(1):76-81. https://doi.org/10.1053/j.semnuclmed.2017.09.007https://doi.org/10.1053/j.semnuclmed.2017.09.007

Cohen D, Luttwak E, Beyar-Katz, O, et al., 2022. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging, 49(3):953-962. https://doi.org/10.1007/s00259-021-05551-5https://doi.org/10.1007/s00259-021-05551-5

Coiffier B, Lepage E, Brière J, et al., 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346(4):235-242. https://doi.org/10.1056/NEJMoa011795https://doi.org/10.1056/NEJMoa011795

Cottereau AS, Versari A, Loft A, et al., 2018. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 131(13):1456-1463. https://doi.org/10.1182/blood-2017-07-795476https://doi.org/10.1182/blood-2017-07-795476

Demeestere I, Racape J, Dechene J, et al., 2021. Gonadal function recovery in patients with advanced Hodgkin lymphoma treated with a PET-adapted regimen: prospective analysis of a randomized phase III trial (AHL2011). J Clin Oncol, 39(29):3251-3260. https://doi.org/10.1200/JCO.21.00068https://doi.org/10.1200/JCO.21.00068

Derlin T, Schultze-Florey C, Werner RA, et al., 2021. 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Ann Nucl Med, 35(1):132-138. https://doi.org/10.1007/s12149-020-01544-whttps://doi.org/10.1007/s12149-020-01544-w

Dührsen U, Müller S, Hertenstein B, et al., 2018. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol, 36(20):2024-2034. https://doi.org/10.1200/JCO.2017.76.8093https://doi.org/10.1200/JCO.2017.76.8093

Dupuis J, Itti E, Rahmouni A, et al., 2009. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol, 20(3):503-507. https://doi.org/10.1093/annonc/mdn671https://doi.org/10.1093/annonc/mdn671

Eertink JJ, Burggraaff CN, Heymans MW, et al., 2021. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv, 5(9):2375-2384. https://doi.org/10.1182/bloodadvances.2021004467https://doi.org/10.1182/bloodadvances.2021004467

Engert A, Plütschow A, Eich HT, et al., 2010. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med, 363(7):640-652. https://doi.org/10.1056/NEJMoa1000067https://doi.org/10.1056/NEJMoa1000067

Fermé C, Eghbali H, Meerwaldt JH, et al., 2007. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med, 357(19):1916-1927. https://doi.org/10.1056/NEJMoa064601https://doi.org/10.1056/NEJMoa064601

Ferrari C, Maggialetti N, Masi T, et al., 2021. Early evaluation of immunotherapy response in lymphoma patients by 18F-FDG PET/CT: a literature overview. J Pers Med, 11(3):217. https://doi.org/10.3390/jpm11030217https://doi.org/10.3390/jpm11030217

Fiad NL, Prates MV, Fernandez I, et al., 2022. P1082: safety and efficacy analysis in older patients treated within the GATLA LH-05 protocol: PET-adapted therapy after 3 cycles of ABVD for all stages of Hodgkin lymphoma. HemaSphere, 6:972-973. https://doi.org/10.1097/01.HS9.0000847196.45811.7ehttps://doi.org/10.1097/01.HS9.0000847196.45811.7e

Follows GA, Barrington SF, Bhuller KS, et al., 2022. Guideline for the first-line management of Classical Hodgkin Lymphoma—a British Society for Haematology guideline. Br J Haematol, 197(5):558-572. https://doi.org/10.1111/bjh.18083https://doi.org/10.1111/bjh.18083

Friedberg JW, 2011. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program, 2011(1):498-505. https://doi.org/10.1182/asheducation-2011.1.498https://doi.org/10.1182/asheducation-2011.1.498

Fuchs M, Goergen H, Kobe C, et al., 2019. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol, 37(31):2835-2845. https://doi.org/10.1200/JCO.19.00964https://doi.org/10.1200/JCO.19.00964

Fuertes S, Setoain X, Lopez-Guillermo A, et al., 2013. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging, 40(4):‍496-504. https://doi.org/10.1007/s00259-012-2320-8https://doi.org/10.1007/s00259-012-2320-8

Gallamini A, Hutchings M, Rigacci L, et al., 2007. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol, 25(24):3746-3752. https://doi.org/10.1200/JCO.2007.11.6525https://doi.org/10.1200/JCO.2007.11.6525

Gallamini A, Rossi A, Patti C, et al., 2019. Consolidation radiotherapy could be omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD. Final analysis of the randomized HD0607 trial. Hematol Oncol, 37(S2):147-148. https://doi.org/10.1002/hon.105_2629https://doi.org/10.1002/hon.105_2629

Gallamini A, Rossi A, Patti C, et al., 2020. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: final analysis of the randomized GITIL/FIL HD0607 trial. J Clin Oncol, 38(33):‍3905-3913. https://doi.org/10.1200/JCO.20.00935https://doi.org/10.1200/JCO.20.00935

Han HS, Escalón MP, Hsiao B, et al., 2009. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol, 20(2):309-318. https://doi.org/10.1093/annonc/mdn629https://doi.org/10.1093/annonc/mdn629

Hertzberg M, Gandhi MK, Trotman J, et al., 2017. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)‍-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102(2):356-363. https://doi.org/10.3324/haematol.2016.154039https://doi.org/10.3324/haematol.2016.154039

Imber BS, Sadelain M, DeSelm C, et al., 2020. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol, 190(1):45-51. https://doi.org/10.1111/bjh.16541https://doi.org/10.1111/bjh.16541

Johnson P, Federico M, Kirkwood A, et al., 2016. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med, 374(25):2419-2429. https://doi.org/10.1056/NEJMoa1510093https://doi.org/10.1056/NEJMoa1510093

Josting A, Wiedenmann S, Franklin J, et al., 2003. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol, 21(18):3440-3446. https://doi.org/10.1200/JCO.2003.07.160https://doi.org/10.1200/JCO.2003.07.160

Juweid ME, Stroobants S, Hoekstra OS, et al., 2007. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol, 25(5):571-578. https://doi.org/10.1200/JCO.2006.08.2305https://doi.org/10.1200/JCO.2006.08.2305

Knowles SM, Wu AM, 2012. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol, 30(31):3884-3892. https://doi.org/10.1200/JCO.2012.42.4887https://doi.org/10.1200/JCO.2012.42.4887

Kreissl S, Goergen H, Buehnen I, et al., 2021. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol, 8(6):e398-e409. https://doi.org/10.1016/S2352-3026(21)00101-0https://doi.org/10.1016/S2352-3026(21)00101-0

Kurtz DM, Scherer F, Jin MC, et al., 2018. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol, 36(28):‍2845-2853. https://doi.org/10.1200/JCO.2018.78.5246https://doi.org/10.1200/JCO.2018.78.5246

LaCasce AS, Dockter T, Ruppert AS, et al., 2021. CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL). J Clin Oncol, 39(S15):7507. https://doi.org/10.1200/JCO.2021.39.15_suppl.7507https://doi.org/10.1200/JCO.2021.39.15_suppl.7507

Larson SM, Erdi Y, Akhurst T, et al., 1999. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging, 2(3):159-171. https://doi.org/10.1016/s1095-0397(99)00016-3https://doi.org/10.1016/s1095-0397(99)00016-3

le Gouill S, Ghesquières H, Oberic L, et al., 2021. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood, 137(17):2307-2320. https://doi.org/10.1182/blood.2020008750https://doi.org/10.1182/blood.2020008750

Lin C, Itti E, Haioun C, et al., 2007. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med, 48(10):1626-1632. https://doi.org/10.2967/jnumed.107.042093https://doi.org/10.2967/jnumed.107.042093

Luminari S, Biasoli I, Versari A, et al., 2014. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol, 25(2):442-447. https://doi.org/10.1093/annonc/mdt562https://doi.org/10.1093/annonc/mdt562

Mamot C, Klingbiel D, Hitz, F, et al., 2015. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol, 33(23):2523-2529. https://doi.org/10.1200/JCO.2014.58.9846https://doi.org/10.1200/JCO.2014.58.9846

Matasar MJ, Zelenetz AD, 2008. Overview of lymphoma diagnosis and management. Radiol Clin North Am, 46(2):175-198. https://doi.org/10.1016/j.rcl.2008.03.005https://doi.org/10.1016/j.rcl.2008.03.005

Matasar MJ, Ford JS, Riedel ER, et al., 2015. Late morbidity and mortality in patients with Hodgkin’s lymphoma treated during adulthood. J Natl Cancer Inst, 107(4):djv018. https://doi.org/10.1093/jnci/djv018https://doi.org/10.1093/jnci/djv018

Mehta-Shah N, Ito K, Bantilan K, et al., 2019. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv, 3(2):187-197. https://doi.org/10.1182/bloodadvances.2018024075https://doi.org/10.1182/bloodadvances.2018024075

Moskowitz CH, Schöder H, Teruya-Feldstein J, et al., 2010. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol, 28(11):1896-1903. https://doi.org/10.1200/JCO.2009.26.5942https://doi.org/10.1200/JCO.2009.26.5942

Mounier N, Brice P, Bologna S, et al., 2014. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0‍‒‍2) of the LYSA H34 randomized trial. Ann Oncol, 25(8):1622-1628. https://doi.org/10.1093/annonc/mdu189https://doi.org/10.1093/annonc/mdu189

Pardal E, Coronado M, Martín A, et al., 2014. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol, 167(3):327-336. https://doi.org/10.1111/bjh.13036https://doi.org/10.1111/bjh.13036

Pavlovsky A, Fernandez I, Kurgansky N, et al., 2019. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br J Haematol, 185(5):865-873. https://doi.org/10.1111/bjh.15838https://doi.org/10.1111/bjh.15838

Pavlovsky A, Fiad NL, Prates MV, et al., 2022. P1081: PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial. HemaSphere, 6:971-972. https://doi.org/10.1097/01.HS9.0000847192.97515.16https://doi.org/10.1097/01.HS9.0000847192.97515.16

Persky DO, Li HL, Stephens DM, et al., 2020. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup National Clinical Trials Network study S1001. J Clin Oncol, 38(26):3003-3011. https://doi.org/10.1200/JCO.20.00999https://doi.org/10.1200/JCO.20.00999

Pregno P, Chiappella A, Bellò M, et al., 2012. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood, 119(9):2066-2073. https://doi.org/10.1182/blood-2011-06-359943https://doi.org/10.1182/blood-2011-06-359943

Press OW, Li HL, Schöder H, et al., 2016. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol, 34(17):2020-2027. https://doi.org/10.1200/JCO.2015.63.1119https://doi.org/10.1200/JCO.2015.63.1119

Radford J, Illidge T, Counsell N, et al., 2015. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med, 372(17):1598-1607. https://doi.org/10.1056/NEJMoa1408648https://doi.org/10.1056/NEJMoa1408648

Ricardi U, Levis M, Evangelista A, et al., 2021. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv, 5(21):4504-4514. https://doi.org/10.1182/bloodadvances.2021005150https://doi.org/10.1182/bloodadvances.2021005150

Rigacci L, Puccini B, Zinzani PL, et al., 2015. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the Fondazione Italiana Linfomi (FIL). Am J Hematol, 90(6):499-503. https://doi.org/10.1002/ajh.23994https://doi.org/10.1002/ajh.23994

Safar V, Dupuis J, Itti E, et al., 2012. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol, 30(2):‍184-190. https://doi.org/10.1200/JCO.2011.38.2648https://doi.org/10.1200/JCO.2011.38.2648

Sehn LH, Scott DW, Villa D, et al., 2019. Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood, 134(S1):401. https://doi.org/10.1182/blood-2019-128722https://doi.org/10.1182/blood-2019-128722

Shah NN, Nagle SJ, Torigian DA, et al., 2018. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy, 20(12):1415-1418. https://doi.org/10.1016/j.jcyt.2018.10.003https://doi.org/10.1016/j.jcyt.2018.10.003

Shaikh PM, Alite F, Pugliese N, et al., 2020. Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis. Leuk Lymphoma, 61(7):1610-1617. https://doi.org/10.1080/10428194.2020.1725506https://doi.org/10.1080/10428194.2020.1725506

Sieniawski M, Reineke T, Josting A, et al., 2008. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol, 19(10):1795-1801. https://doi.org/10.1093/annonc/mdn376https://doi.org/10.1093/annonc/mdn376

Stephens DM, Li HL, Schöder H, et al., 2019. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15):1238-1246. https://doi.org/10.1182/blood.2019000719https://doi.org/10.1182/blood.2019000719

Stewart DA, Kloiber R, Owen C, et al., 2014. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leuk Lymphoma, 55(9):2064-2070. https://doi.org/10.3109/10428194.2013.862242https://doi.org/10.3109/10428194.2013.862242

Straus DJ, Jung SH, Pitcher B, et al., 2018. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 132(10):‍1013-1021. https://doi.org/10.1182/blood-2018-01-827246https://doi.org/10.1182/blood-2018-01-827246

Swinnen LJ, Li HL, Quon A, 2015. Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol, 170(1):56-65. https://doi.org/10.1111/bjh.13389https://doi.org/10.1111/bjh.13389

Toledano MN, Desbordes P, Banjar A, et al., 2018. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging, 45(5):680-688. https://doi.org/10.1007/s00259-017-3907-xhttps://doi.org/10.1007/s00259-017-3907-x

Vijenthira A, Chan K, Cheung MC, et al., 2020. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. Lancet Haematol, 7(2):e146-e156. https://doi.org/10.1016/S2352-3026(19)30218-2https://doi.org/10.1016/S2352-3026(19)30218-2

Villa D, Sehn LH, Aquino-Parsons C, et al., 2018. Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 103(12):e590-e593. https://doi.org/10.3324/haematol.2018.196782https://doi.org/10.3324/haematol.2018.196782

Viviani S, Zinzani PL, Rambaldi A, et al., 2011. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med, 365(3):‍203-212. https://doi.org/10.1056/NEJMoa1100340https://doi.org/10.1056/NEJMoa1100340

Zanoni L, Mattana F, Calabrò D, et al., 2021. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. Eur J Radiol, 141:109793. https://doi.org/10.1016/j.ejrad.2021.109793https://doi.org/10.1016/j.ejrad.2021.109793

Zasadny KR, Kison PV, Francis IR, et al., 1998. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging, 1(2):123-129. https://doi.org/10.1016/s1095-0397(98)00007-7https://doi.org/10.1016/s1095-0397(98)00007-7

Zhu CT, Zhao Y, Yu F, et al., 2021. Tumor flare reaction in a classic Hodgkin lymphoma patient treated with brentuximab vedotin and tislelizumab: a case report. Front Immunol, 12:756583. https://doi.org/10.3389/fimmu.2021.756583https://doi.org/10.3389/fimmu.2021.756583

Zinzani PL, Broccoli A, Gioia DM, et al., 2016. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol, 34(12):1376-1385. https://doi.org/10.1200/JCO.2015.63.0699https://doi.org/10.1200/JCO.2015.63.0699

浏览量

Downloads

CSCD

工具集

关联资源

暂无数据